publication date: Dec. 7, 2018

NCI Trials

NCI Trials for December

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

For further information, contact the principal investigator listed.

 

Phase I 10218

A Phase Ib Trial of CB-839 in Combination with Radiation Therapy and Temozolomide in Patients with IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma

Mayo Clinic Cancer Center LAO

Kizilbash, Sani Haider

(507) 284-2017

 

Phase I/II 10186

A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination with Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma

Duke University – Duke Cancer Institute LAO

Huang, Jiayi

(314) 747-8567

 

Phase II 10146

Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + MEDI4736 (Durvalumab) + Neoantigen Vaccine Vs. Nab-Paclitaxel + MEDI4736 (Durvalumab) in Patients with Metastatic Triple Negative Breast Cancer

Duke University – Duke Cancer Institute LAO

Gillanders, William E.

(314) 747-0072

 

Phase II 9598B

A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients with BRAF V600 Mutation Positive Lesions in Erdheim Chester Disease

M D Anderson Cancer Center

Janku, Filip

(713) 563-2632

 

Phase II A041703

A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease

Alliance for Clinical Trials in Oncology

Wieduwilt, Matthew Joseph

Continue reading NCI Trials for December 2018

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.